ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 092,11
-0,61%
Dow Jones
39 824,32
-0,12%
DAX
18 680,20
-0,25%
Brent Oil
82,20
-0,30%
Bitcoin
70 318,69
0,27%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Renalytix PLC (RNLX)

  7. Renalytix PLC (RNLX) Actualités

RNLX Renalytix PLC

0,4396
0,004 (0,92%)
Dernière mise à jour : 18:09:06
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Renalytix PLC RNLX NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,004 0,92% 0,4396 18:09:06
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,45 0,423 0,4524 0,4356
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
15/5/202416:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/5/202415:23EDGAR2Form 8-K - Current report
15/5/202413:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
15/5/202413:00EDGAR2Form 8-K - Current report
15/5/202413:00GLOBERenalytix Reports Financial Results for Third Quarter of..
09/5/202413:00GLOBERenalytix to Report Financial Results for Third Quarter..
08/4/202413:00GLOBERenalytix Announces Financing with Expected Size of up to $4..
14/3/202412:00GLOBEKidneyIntelX™ included in Final KDIGO 2024 Clinical..
15/2/202413:00GLOBERenalytix Reports Financial Results for Second Quarter of..
15/2/202413:00EDGAR2Form 8-K - Current report
14/2/202422:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/2/202415:00GLOBERenalytix to Participate in the BTIG MedTech, Digital..
17/1/202413:15EDGAR2Form 8-K - Current report
10/1/202413:15EDGAR2Form 8-K - Current report
10/1/202413:00GLOBENew published data demonstrates KidneyIntelX™ has broad..
29/12/202322:02EDGAR2Form 8-K - Current report
17/11/202322:01EDGAR2Form ARS - Annual Report to Security Holders
14/11/202313:00GLOBERenalytix Reports Financial Results for First Quarter of..
07/11/202313:00GLOBERenalytix to Report Financial Results for First Quarter..
03/11/202321:04EDGAR2Form PRE 14A - Other preliminary proxy statements
24/10/202314:00EDGAR2Form 8-K - Current report
06/10/202313:00GLOBEUS Patent Office Allows Patent Claims for Intellectual..
28/9/202313:00GLOBERenalytix Reports Full Year Fiscal 2023 Results
25/9/202313:00GLOBERenalytix to Report Financial Results for Fourth Quarter and..
08/9/202322:04EDGAR2Form 8-K - Current report
07/9/202313:00GLOBERenalytix Appoints Senior Executive Howard Doran as Chief..
03/8/202313:00GLOBERenalytix Clinical Advisory Board Formed to Support..
21/7/202313:00GLOBERenalytix Announces Middle East Distribution Agreement with..
07/7/202313:00GLOBELate-Breaking KidneyIntelX Evidence Released at 83rd..
03/7/202313:00GLOBERenalytix Appoints Financial Executive Catherine Coste to..
30/6/202300:58DJNRenalytix Gets FDA De Novo Marketing Authorization for..
30/6/202300:01GLOBEFDA Grants De Novo Marketing Authorization for..
15/6/202313:00GLOBEKidneyIntelX™ Clinical Decision Impact / Validation and..
09/6/202313:00GLOBERenalytix Reports Financial Results for Third Quarter of..
05/6/202313:00GLOBERenalytix to Report Third Quarter Fiscal Year 2023 Financial..
25/5/202313:00GLOBERenalytix selects EVERSANA® to expand commercialization of..

Dernières Valeurs Consultées

NASDAQ
RNLX
Renalytix
USOTC
JPPTY
Japan Post Bank (PK)
ASX
CTDN
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés